Brian Resnick, DO
Internal Medicine · Telford, PANPI 1144305012
Payments from drug & device makers
Across 358 payments — averaging $18.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Pfizer$803
- Johnson & Johnson$700
- Boehringer Ingelheim$577
- GSK$504
- AstraZeneca$477
- plus $2K from 24 others
What the payments were for
- Food & beverage$6,41599%
- Education$160%
- Other$651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 60 | $1,052 |
| Pfizer | 40 | $803 |
| Johnson & Johnson | 27 | $700 |
| Boehringer Ingelheim | 39 | $577 |
| GSK | 29 | $504 |
| AstraZeneca | 30 | $477 |
| Lilly USA, LLC | 21 | $347 |
| Merck | 22 | $347 |
| Bayer | 17 | $345 |
| AbbVie(2 entities) | 13 | $213 |
| Astellas Pharma US Inc | 7 | $140 |
| Amgen(2 entities) | 5 | $131 |
| Biohaven Pharmaceuticals, Inc. | 6 | $128 |
| Exact Sciences | 5 | $125 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $110 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $78 |
| Welch Allyn | 1 | $65 |
| Amarin Pharma, Inc. | 4 | $64 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $60 |
| Galderma Laboratories, L.p. | 3 | $44 |
| Merz North America, Inc. | 1 | $31 |
| Indivior Inc. | 2 | $26 |
| Revance Therapeutics, Inc. | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Novartis | 1 | $18 |
| Abbott | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
| Orexo US, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Endogastric Solutions, Inc | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,497 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 42 | $61,640 |
| OzempicSemaglutide | 21 | $27,343 |
| EliquisApixaban | 28 | $27,091 |
| MounjaroTirzepatide | 13 | $26,290 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 170 | $23,442 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 68 | $19,901 |
| JanuviaSitagliptin Phosphate | 23 | $13,639 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 59 | $12,162 |
| FarxigaDapagliflozin Propanediol | 19 | $10,651 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $8,992 |
| TrintellixVortioxetine Hydrobromide | 13 | $6,148 |
| MyrbetriqMirabegron | 12 | $5,821 |
| OxycontinOxycodone Hcl | 12 | $5,404 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $3,316 |
| Atorvastatin Calcium | 213 | $2,391 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $577 | $61,64042 claims |
| GSKArexvy, Shingrix, Trelegy Ellipta | $504 | $41,055141 claims |
| Novo NordiskOzempic | $1,052 | $27,34321 claims |
| PfizerEliquis | $803 | $27,09128 claims |
| Lilly USA, LLCMounjaro | $347 | $26,29013 claims |
| MerckJanuvia | $347 | $13,63923 claims |
| AstraZenecaFarxiga | $477 | $10,65119 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $78 | $6,14813 claims |
| Astellas Pharma US IncMyrbetriq | $140 | $5,82112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Telford
- Jonathan EpsteinPhiladelphia$13.1M
- Siddharth ShethPittsburgh$11M
- Nathan PatelTannersville$9.5M
- Pitamber DevgonPhiladelphia$7.5M
- Christopher StillDanville$7.1M
- Liza VillaruzPittsburgh$6.6M
- Paul HartleyUniontown$4.9M
- Victor KoladeSayre$4.7M
- Michael OliverBeaver$4.7M
- Raman PurighallaPittsburgh$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.